Active substance
Pyridostigmine
- SFDA 1
- US FDA 22
- Health Canada 4
- US price lines 4
- NHS prices 2
- WHO EML 2
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| MESTINON 60MG TABLET | 60 mg | Tablet · Oral use | 20 Bottle | SAR 22.25 | NCE · Prescription | MEDA Pharmaceuticals Switzerland GmbH | Valid |
Indications — CHI Daman Drug Formulary
HYPOTENSION; MYASTHENIA GRAVIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MESTINON | 60MG | tablet · oral | BAUSCH | Prescription | 6 Apr 1955 |
| MESTINON | 5MG/ML | injectable · injection | BAUSCH | Prescription | 2 Oct 1955 |
| MESTINON | 180MG | tablet, extended release · oral | BAUSCH | Prescription | 12 Jan 1959 |
| MESTINON | 60MG/5ML | syrup · oral | BAUSCH | Prescription | 25 Jan 1965 |
| REGONOL | 5MG/ML | injectable · injection | SANDOZ | Prescription | 14 Aug 1973 |
| PYRIDOSTIGMINE BROMIDE | 60MG; 30MG | tablet · oral | IMPAX LABS | Prescription | 24 Apr 2003 |
| PYRIDOSTIGMINE BROMIDE | 60MG | tablet · oral | ANI PHARMS | Prescription | 8 Oct 2003 |
| PYRIDOSTIGMINE BROMIDE | 60MG | tablet · oral | ZYDUS PHARMS | Prescription | 22 Jun 2015 |
| PYRIDOSTIGMINE BROMIDE | 180MG | tablet, extended release · oral | ALVOGEN | Prescription | 26 Jun 2015 |
| PYRIDOSTIGMINE BROMIDE | 180MG | tablet, extended release · oral | RISING | Prescription | 15 Aug 2017 |
| PYRIDOSTIGMINE BROMIDE | 60MG; 30MG | tablet · oral | MLV | Prescription | 20 Jul 2018 |
| PYRIDOSTIGMINE BROMIDE | 60MG/5ML | syrup · oral | NOVITIUM PHARMA | Prescription | 8 Mar 2019 |
| PYRIDOSTIGMINE BROMIDE | 60MG/5ML | syrup · oral | RISING | Prescription | 9 Jan 2020 |
| PYRIDOSTIGMINE BROMIDE | 60MG/5ML | syrup · oral | AMNEAL | Prescription | 10 Jan 2020 |
| PYRIDOSTIGMINE BROMIDE | 60MG/5ML | syrup · oral | MILLA PHARMS | Prescription | 19 Apr 2022 |
| PYRIDOSTIGMINE BROMIDE | 60MG/5ML | syrup · oral | MSN | Prescription | 21 Sep 2023 |
| PYRIDOSTIGMINE BROMIDE | 30MG | tablet · oral | SOLVAY | Discontinued | 27 Nov 1990 |
| PYRIDOSTIGMINE BROMIDE | 60MG | tablet · oral | IMPAX LABS INC | Discontinued | 26 Dec 2002 |
| PYRIDOSTIGMINE BROMIDE | 30MG | tablet · oral | US ARMY | Discontinued | 5 Feb 2003 |
| PYRIDOSTIGMINE BROMIDE | 30MG | tablet · oral | ANI PHARMS | Discontinued | 8 Oct 2003 |
| PYRIDOSTIGMINE BROMIDE | 180MG | tablet, extended release · oral | IMPAX LABS INC | Discontinued | 15 Sep 2015 |
| PYRIDOSTIGMINE BROMIDE | 105MG | tablet, extended release · oral | AMNEAL | Discontinued | 4 Oct 2024 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| JAMP PYRIDOSTIGMINE BROMIDE | 02508362 | 60 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| MESTINON | 00869961 | 60 MG | TABLET · ORAL | BAUSCH HEALTH, CANADA INC. |
| MESTINON-SR | 00869953 | 180 MG | TABLET (EXTENDED-RELEASE) · ORAL | BAUSCH HEALTH, CANADA INC. |
| RIVA-PYRIDOSTIGMINE | 02495643 | 60 MG | TABLET · ORAL | LABORATOIRE RIVA INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | PYRIDOSTIGMINE 60 MG/5 ML SOLN | $0.56484 | per ML | 23 Sep 2026 |
| US NADAC | PYRIDOSTIGMINE BR 30 MG TABLET | $6.94704 | per EA | 23 Sep 2026 |
| US NADAC | PYRIDOSTIGMINE BR 60 MG TABLET | $0.24872 | per EA | 23 Sep 2026 |
| US NADAC | PYRIDOSTIGMINE ER 180 MG TAB | $3.99632 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Pyridostigmine bromide 12mg/1ml oral solution sugar free | £90.00 | 150 ml | 1 Oct 2026 |
| NHS Drug Tariff | Pyridostigmine bromide 60mg tablets | £14.24 | 200 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 5.2.2. Medicines for myasthenia gravis · complementary
Myasthenia gravis
Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide) | Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide) - 20. Muscle relaxants (peripherally-acting) and cholinesterase inhibitors · complementary
Myasthenia gravis
Parenteral > General injections > IV: 5 mg per mL in ampoule or vial (pyridostigmine bromide) | Oral > Solid > tablet: 60 mg scored (pyridostigmine bromide)
Safety signals and safety-related labeling changes
- US FDA 12 May 2026 PYRIDOSTIGMINE BROMIDE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 26 Sep 2025 PYRIDOSTIGMINE BROMIDE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.